FCM
VRTX icon

Fourpath Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Fourpath Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$753K Sell
1,687
-81
-5% -$37.8K 0.11% 124
2025
Q4 		$802K Buy
1,768
+109
+7% +$47K 0.11% 114
2025
Q3 		$650K Buy
1,659
+280
+20% +$117K 0.09% 131
2025
Q2 		$614K Sell
1,379
-188
-12% -$86.6K 0.1% 127
2025
Q1 		$760K Sell
1,567
-130
-8% -$60.6K 0.13% 102
2024
Q4 		$683K Sell
1,697
-2
-0.1% -$927 0.13% 113
2024
Q3 		$790K Buy
1,699
+30
+2% +$14.4K 0.15% 106
2024
Q2 		$782K Sell
1,669
-161
-9% -$69.9K 0.58% 37
2024
Q1 		$765K Sell
1,830
-75
-4% -$31.7K 0.53% 42
2023
Q4 		$775K Sell
1,905
-136
-7% -$50.2K 0.53% 40
2023
Q3 		$710K Sell
2,041
-56
-3% -$19.6K 0.53% 41
2023
Q2 		$738K Sell
2,097
-32
-2% -$10.8K 0.89% 36
2023
Q1 		$671K Sell
2,129
-27
-1% -$8.1K 0.47% 54
2022
Q4 		$623K Sell
2,156
-71
-3% -$21.6K 0.45% 57
2022
Q3 		$645K Sell
2,227
-596
-21% -$171K 0.44% 54
2022
Q2 		$795K Sell
2,823
-769
-21% -$206K 0.49% 48
2022
Q1 		$937K Sell
3,592
-354
-9% -$84K 0.37% 47
2021
Q4 		$867K Buy
+3,946
New +$767K 0.33% 55

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fourpath Capital Management's VRTX Position: Q1 2026 in Review

Fourpath Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 4.6% in Q1 2026, selling an estimated $37.8K and leaving 1,687 shares worth $753K. The position accounts for 0.11% of the portfolio, ranked #124.

Fourpath Capital Management first reported a position in VRTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $937K in Q1 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Fourpath Capital Management held 1,687 shares of Vertex Pharmaceuticals worth $753K as of Q1 2026.
  • Fourpath Capital Management sold 81 Vertex Pharmaceuticals shares in Q1 2026, an estimated $37.8K.
  • Vertex Pharmaceuticals made up 0.11% of Fourpath Capital Management's portfolio in Q1 2026, its #124 holding.
  • Fourpath Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Fourpath Capital Management's Vertex Pharmaceuticals position peaked at $937K in Q1 2022.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.